Long-term response to first-line pazopanib therapy in mRCC patients: A multicenter Italian experience

Andrea Sbrana; Elisa Biasco; Federico Paolieri; Erica Palesandro; Claudia Caserta; Roberto Iacovelli; Beatrice Detti; Daniele Santini; Alessandra Mosca; Franco Morelli; Giuseppe Fornarini; Ugo De Giorgi; Cristina Masini; Luca Galli

doi:10.21873/anticanres.12807

Long-term response to first-line pazopanib therapy in mRCC patients: A multicenter Italian experience

Andrea Sbrana, Elisa Biasco, Federico Paolieri, Erica Palesandro, Claudia Caserta, Roberto Iacovelli, Beatrice Detti, Daniele Santini, Alessandra Mosca, Franco Morelli, Giuseppe Fornarini, Ugo De Giorgi, Cristina Masini, Luca Galli

Research output: Contribution to journal › Article › peer-review

Abstract

Background/Aim: The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Patients and Methods: Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. Results: In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Conclusion: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.

Original language	English
Pages (from-to)	4913-4918
Number of pages	6
Journal	Anticancer Research
Volume	38
Issue number	8
DOIs	https://doi.org/10.21873/anticanres.12807
Publication status	Published - Aug 1 2018

Keywords

First-line
MRCC
Pazopanib
Response

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.21873/anticanres.12807

Cite this

Sbrana, A., Biasco, E., Paolieri, F., Palesandro, E., Caserta, C., Iacovelli, R., Detti, B., Santini, D., Mosca, A., Morelli, F., Fornarini, G., De Giorgi, U., Masini, C., & Galli, L. (2018). Long-term response to first-line pazopanib therapy in mRCC patients: A multicenter Italian experience. Anticancer Research, 38(8), 4913-4918. https://doi.org/10.21873/anticanres.12807

Sbrana, A, Biasco, E, Paolieri, F, Palesandro, E, Caserta, C, Iacovelli, R, Detti, B, Santini, D, Mosca, A, Morelli, F , Fornarini, G , De Giorgi, U , Masini, C & Galli, L 2018, 'Long-term response to first-line pazopanib therapy in mRCC patients: A multicenter Italian experience', Anticancer Research, vol. 38, no. 8, pp. 4913-4918. https://doi.org/10.21873/anticanres.12807

@article{e2426eb2640947c19ff2215bece9fd74,

title = "Long-term response to first-line pazopanib therapy in mRCC patients: A multicenter Italian experience",

abstract = "Background/Aim: The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Patients and Methods: Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. Results: In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Conclusion: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.",

keywords = "First-line, MRCC, Pazopanib, Response",

author = "Andrea Sbrana and Elisa Biasco and Federico Paolieri and Erica Palesandro and Claudia Caserta and Roberto Iacovelli and Beatrice Detti and Daniele Santini and Alessandra Mosca and Franco Morelli and Giuseppe Fornarini and {De Giorgi}, Ugo and Cristina Masini and Luca Galli",

year = "2018",

month = aug,

day = "1",

doi = "10.21873/anticanres.12807",

language = "English",

volume = "38",

pages = "4913--4918",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "8",

}

TY - JOUR

T1 - Long-term response to first-line pazopanib therapy in mRCC patients

T2 - A multicenter Italian experience

AU - Sbrana, Andrea

AU - Biasco, Elisa

AU - Paolieri, Federico

AU - Palesandro, Erica

AU - Caserta, Claudia

AU - Iacovelli, Roberto

AU - Detti, Beatrice

AU - Santini, Daniele

AU - Mosca, Alessandra

AU - Morelli, Franco

AU - Fornarini, Giuseppe

AU - De Giorgi, Ugo

AU - Masini, Cristina

AU - Galli, Luca

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background/Aim: The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Patients and Methods: Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. Results: In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Conclusion: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.

AB - Background/Aim: The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Patients and Methods: Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. Results: In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Conclusion: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.

KW - First-line

KW - MRCC

KW - Pazopanib

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=85050810011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050810011&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12807

DO - 10.21873/anticanres.12807

M3 - Article

C2 - 30061269

AN - SCOPUS:85050810011

SN - 0250-7005

VL - 38

SP - 4913

EP - 4918

JO - Anticancer Research

JF - Anticancer Research

IS - 8

ER -

Long-term response to first-line pazopanib therapy in mRCC patients: A multicenter Italian experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this